|
Venezuela Pharmaceuticals & Healthcare Report |
Was: $1030.00 | |
| Now: $875.00 | ||
| You save: $155.00 (15%) |
The Venezuela Pharmaceuticals and Healthcare Report
Independent 5-year pharmaceutical and healthcare industry forecasts for Venezuela .
Original pharmaceutical and healthcare market research and pharmaceutical and healthcare sector trend analysis for the Venezuelan pharmaceutical and healthcare industry.
Competitive intelligence, Venezuelan pharmaceutical and healthcare company rankings and SWOT analyses on international and domestic pharmaceutical and healthcare companies in the Venezuelan market.
The Venezuela Pharmaceuticals and Healthcare Report has been researched at source and features the latest available data and forecasts to end- covering drugs and healthcare expenditure, the prescription, OTC and generics markets, and foreign trade; company rankings and competitive landscapes including multinational and national drugs companies; and analysis of latest industry news, trends and regulatory developments.
Business Monitor International’s Venezuela Pharmaceuticals and Healthcare Report provides industry professionals, market investors and corporate and financial services analysts with independent forecasts and competitive intelligence on the Venezuelan pharmaceutical and healthcare industry.
Key Benefits of Report
- Benchmark BMI’s Independent 5-year Pharmaceutical and Healthcare Industry Forecasts on Venezuela to test other views – a key input for successful budgeting and strategic business planning in the Venezuelan pharmaceutical and healthcare market.
- Target Business Opportunities & Risks in the Venezuelan Pharmaceutical and Healthcare Sector through our reviews of latest industry trends, regulatory changes and major deals, projects and investments in Venezuela .
- Exploit The Latest Competitive Venezuelan Pharmaceutical and Healthcare Intelligence & company SWOTS on your competitors and peers through company rankings by sales, market share and ownership structure – includes multi-national and national companies in Venezuela .
Coverage
Executive Summary & Industry SWOT
An at-a-glance perspective on latest regulatory developments, key forecast indicators and major corporate developments, covering the prescription, OTC and generics markets. The SWOT outlines strategic factors which affect BMI’s forecast analysis, and taken together with BMI’s Economic and Business Environment SWOTS, give a complete overview of market climate.
Market Summary
Outline of market characteristics, growth factors, leading therapeutic segments and a competitivness of the market.
Regulatory Regime
Guide to and analysis of country intellectual property developments and pricing & reimbursement issues, which constitute the regulatory make-up of the market.
Industry Developments
Focus on government healthcare reforms, epidemiological trends, company M&As, product launches, market entries, FDI activity, R&D and patent legislation.
BMI 5-Year Industry Forecast
5-Year Forecasts to end- for all key industry indicators (see list below), supported by explicit assumptions, plus analysis of key downside risks to the main forecast, including:
- Drug market expenditure (US$bn); drug expenditure per capita (US$); as % of gdp
- Prescription drug market (US$bn)/as % of total market; sales by alimentary tract/metabolism; antibiotics, cardiovascular, central nervous system, oncology, musculoskeletal and respiratory system
- OTC market (US$bn)/as % of total market (sales by analgesic, cough and cold, digestives, skin treatments, vitamins and minerals)
- Generics market (US$bn)/ as % of total market
- Health expenditure (US$bn, % of gdp and per capita); public sector health expenditure as % of total; number of hospitals; beds, hospital admissions, doctors, births and deaths per 000 population
Forecasts based on bespoke BMI economic modelling, using historical data sets of macroeconomic and industry variables to derive rigorous statistical relationships, anchored in advanced linear regression techniques.
BMI 5-Year Macroeconomic Forecasts
BMI forecasts for all headline macroeconomic indicators, including:
Nominal and real GDP, % real GDP growth, % private consumption growth, % industrial output growth, % consumer price index, % GDP price deflator, exports, imports, trade balance, current account balance, foreign direct investment, exchange rate against US$, government expenditure, external debt
Competitive Landscape & Profiles
Intelligence on the market position of major MNC power houses and indigenous companies. BMI profiles key research-based companies. Company SWOTS are provided for all key strategic players, complete with a company activity overview, its leading products and analysis of business opportunities.
|
Venezuela Pharmaceuticals & Healthcare Report |
Was: $1030.00 | |
| Now: $875.00 | ||
| You save: $155.00 (15%) |
Chapter - Executive Summary |
| Venezuela Pharmaceuticals And Healthcare Industry SWOT Analysis |
| Venezuela Political SWOT Analysis |
| Venezuela Economic SWOT Analysis |
| Venezuela Business Environment SWOT Analysis |
Chapter - Pharmaceutical Business Environment Ratings |
| Table: Business Environment Ratings |
| Limits of Potential Returns |
| Risks to Realisation of Returns |
Chapter - Regulatory Regime |
| Intellectual Property Environment |
| International Collaboration |
| Counterfeit Drugs |
| Pricing And Reimbursement |
| Other Regulatory Issues |
Chapter - Industry Developments |
| Epidemiology |
| Healthcare Sector |
| Hospital Sector |
| Private Healthcare Sector |
| Regional Healthcare Collaboration |
| Pharmaceutical Sector |
| Company Activity |
| OTC Medicines |
| Pharmacy Sector |
| Medical Devices |
Chapter - Industry Forecast Scenario |
| Overall Market Forecast |
| Table: Venezuela – Drug Expenditure Indicators, 2003-2013 |
| Key Growth Factors – Industry |
| Table: Venezuela – Health Expenditure Indicators, 2003-2013 |
| Key Growth Factors – Macroeconomic |
| Major Contraction Ahead |
| Table: Venezuela - Economic Activity |
| Prescription Drug Market Forecast |
| Table: Venezuela – Prescription Market Indicators, 2003-2013 (VEBmn unless otherwise stated) |
| Patented Market Forecast |
| Table: Venezuela – Patented Market Indicators, 2003-2013 |
| Generics Market Forecast |
| Table: Venezuela - Generics Market Indicators, 2003-2013 |
| OTC Market Forecast |
| Table: Venezuela – OTC Market Indicators, 2003-2013 (VEBmn unless otherwise stated) |
| Import/Export Forecasts |
| Table: Venezuela – Import/Export Indicators, 2003-2013 (US$mn) |
| Medical Devices Forecasts |
| Medical Devices Forecasts |
| Table: Venezuela's Medical Device Market, 2006-2013 (US$mn unless otherwise stated) |
| Other Healthcare Data Forecasts |
| Table: Venezuela - Other Healthcare Data, 2003-2013 |
| Key Risks to BMI's Forecast Scenario |
Chapter - Competitive Landscape |
| Company Profiles |
| Leading Multinationals |
| Pfizer |
| Sanofi-Aventis |
| GlaxoSmithKline |
| Boehringer Inglelheim |
| Novartis |
| Merck & Co |
| Indigenous Company Profiles |
| Grupo Farma |
| Elmor |
| Strides Latina (Sumifarma) |
| Calox International |
Chapter - Country Snapshot: Venezuela Demographic Data |
| Section 1: Population |
| Table: Demographic Indicators, 2005-2030 |
| Table: Rural/Urban Breakdown, 2005-2030 |
| Section 2: Education And Healthcare |
| Table: Education, 2002-2005 |
| Table: Vital Statistics, 2005-2030 |
| Section 3: Labour Market And Spending Power |
| Table: Employment Indicators, 2001-2006 |
| Table: Consumer Expenditure, 2000-2012 (US$) |
| How We Generate Our Pharmaceutical Industry Forecasts |
| Pharmaceutical Business Environment Ratings Methodology |
| Ratings Overview |
| Table: Pharmaceutical Business Environment Indicators |
| Weighting |
| Table: Weighting Of Components |
| Sources |
|
Venezuela Pharmaceuticals & Healthcare Report |
Was: $1030.00 | |
| Now: $875.00 | ||
| You save: $155.00 (15%) |
BMI forecasts that the Venezuelan pharmaceutical market will contract in US dollar terms at a rate of 12.2% per annum from 2008-2013. The poor performance is due to overall weaknesses in the Venezuelan economy, which will have a knock on effect on drug market expenditure. BMI’s view is that real GDP will contract substantially by 5.6% in 2009, and 1.7% in 2010. The deep recession and rising inflation will force the government into public spending cuts, which could impact the health sector. Inflation will be a particular problem, and in real terms we expect Venezuela’s drug market to contract by 18% in 2009.
On a regional scale, BMI reports that generic medicines constitute a growing part of the drug markets in Bolivia, Colombia, Peru, Venezuela and Ecuador. A study carried out by Health Action International investigated the availability of 42 branded medicines in 42 private and 34 public sector pharmacies in the four Andean nations and Venezuela. The findings of the project revealed that generic drugs are more widely available than branded medicines across all five countries. The survey showed that public sector pharmacies did not stock patented drugs at all, offering only generic alternatives. Private pharmacies in Ecuador stocked 60% of the cheapest generic versions of the surveyed medicines, Peru stocked 57%, Venezuela stocked 55%, Colombia stocked 50% and Bolivia stocked 48%. Branded medicines fared the best in Venezuela, where 57% of the surveyed drugs were available in private pharmacies. Meanwhile, 52% of the branded medicines were available in Ecuador, 43% in Colombia, 12% in Peru and 5% in Bolivia.
In company terms, Q209 was quiet in Venezuela. However, pharmacy chain Farmatodo closed for 72 hours during January 2009, due to a tax-related investigation. Inconsistencies in the firm’s books since 2006 led to the governmental action. BMI views this development as a sign of improving regulations within the pharmaceutical sector in Venezuela; however, the closure of 103 out of the total 128 outlets affected patient access to medicines.
With such a dire economic prognosis and news that Hugo Chavez has won the right to seek re-election indefinitely, presenting considerable long-term political risk in the country, it is no surprise that Venezuela has fallen once again to the bottom of BMI’s Business Environment Rankings for the Americas region.
|
Venezuela Pharmaceuticals & Healthcare Report |
Was: $1030.00 | |
| Now: $875.00 | ||
| You save: $155.00 (15%) |
Africa |
| Algeria, Egypt, Kenya, Morocco, Nigeria, South Africa and Zimbabwe |
Asia |
| Australia, Bangladesh, China, Hong Kong, India, Indonesia, Japan, Malaysia, Pakistan, Philippines, Singapore, South Korea, Taiwan, Thailand and Vietnam |
Caribbean |
| Puerto Rico |
Europe |
| Belarus, Belgium, Bulgaria, Croatia, Czech Republic, Estonia, France, Germany, Greece, Hungary, Italy, Kazakhstan, Latvia, Lithuania, Moldova, Netherlands, Poland, Portugal, Romania, Russia, Serbia, Slovakia, Slovenia, Spain, Switzerland, Ukraine, United Kingdom and Uzbekistan |
Latin America |
| Argentina, Brazil, Chile, Colombia, Mexico and Peru |
Middle East |
| Bahrain, Iran, Israel, Jordan, Kuwait, Lebanon, Oman, Qatar, Saudi Arabia, Turkey and United Arab Emirates |
North America |
| Canada and United States |
Business Monitor InternationalA Market Leader in Country Risk, Industry Intelligence and Company Research Mermaid House, 2 Puddle Dock, Blackfriars, London EC4V 3DS, UK |
BUSINESS MONITOR INTERNATIONAL's country risk analysis and forecasts, market research on leading industries, and multinational company research is relied upon by corporates, banks, government departments and multilateral organisations in over 125 countries around the world. Country Risk Analysis and Forecasts Industry Intelligence and Market Research Company Research |